Biochemical and behavioural properties of clozapine

Psychopharmacology

Volumn 99, Issue 1 Supplement, 1989, Pages

  Coward, D M ^a   Imperato, A ^b   Urwyler, S ^a   White, T G ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Behavioural effects; Clozapine; D 1 Blockade

Indexed keywords

2 CHLORO 11 (3 DIMETHYLAMINOPROPYLIDENE)MORPHANTHRIDINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; FLUPERLAPINE; FLUPHENAZINE; HALOPERIDOL; HOMOVANILLIC ACID; PROLACTIN; SULPIRIDE; THIORIDAZINE; TILOZEPINE; UNCLASSIFIED DRUG;

BEHAVIOR; CORPUS STRIATUM; HUMAN; LIMBIC SYSTEM; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; TARDIVE DYSKINESIA;

ANIMAL; BEHAVIOR; BEHAVIOR, ANIMAL; CLOZAPINE; DIBENZAZEPINES; HUMAN; NEUROTRANSMITTERS;

EID: 0024425466     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF00442552     Document Type: Article

References (54)

1. Comparison of the pharmacological characteristics of [3-H]SCH 23390 binding to dopamine receptors in vivo in mouse brain
2. Some atypical neuroleptics inhibit [3-H]SCH 23390 binding in vivo
3. Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System)
4. Intranigral GABA antagonists produce dopamine-independent biting in rats
5. Further studies on the mechanism behind scopolamine-induced reversal of anti-stereotypic and cataleptogenic effect of neuroleptics in rats
6. Effects of drugs influencing central serotoninergic mechanisms on haloperidol-induced catalepsy
7. Effect of drugs influencing central 5-hydroxytryptaminergic mechanisms on morphine-induced catalepsy in the rat
8. Brain homovanillic acid: changes over time with antipsychotic drugs
9. Quantitative autoradiographic localisation of the D-1 and D-2 subtypes of dopamine receptors in rat brain
10. Effects of chronic administration of neuroleptic and anticholinergic agents on the densities of D-2 dopamine and muscarinic cholinergic receptors in rat striatum
11. Akinesia after locally-applied morphine near the nucleus raphe pontis of the rat
12. Effect of metergoline, fenfluramine and 8-OHDPAT on catalepsy induced by haloperidol or morphine
13. Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation
14. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons
15. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons
16. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
17. Classical and non-classical neuroleptics induce supersensitivity of nigral GABA-ergic mechanisms in the rat
18. Autoradiographic localization of D-1 and D-2 receptors in the human brain
19. Central D2-dopamine receptor occupancy in schizophrenic patients treated with anti-psychotic drugs
20. PET examination of human D1- and D2-dopamine receptor characteristics. Abstracts of the XVIth C.I.N.P. Congress, Munich
21. GABAergic supersensitivity within the pars reticulata of the rat substantia nigra following chronic haloperidol administration
22. Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra
23. The relationship between parkinsonism and tardive dyskinesia
24. Das Wirkungsprofil eines chemisch neuartigen. Breitbandneuroleptikums der Dibenzodiazepingruppe
25. Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced dyskinesia
26. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis
27. Chronic treatment with dopamine receptor antagonists: behavioural and pharmacological effects on D-1 and D-2 dopamine receptors
28. Effects of the atypical neuroleptics clozapine and fluperlapine on the in vivo dopamine release in the dorsal striatum and in the prefrontal cortex. Abstracts of the XVIth C.I.N.P. Congress, Munich.
29. Clozapine for the treatment-resistant schizophrenic
30. The pharmacology of tardive dyskinesias
31. Repeated atypical neuroleptic administration: effects on central dopamine metabolism monitored by in vivo voltammetry
32. Turnover times of gamma-butyric acid and acetylcholine in nucleus caudatus, nucleus accumbens, globus pallidus and substantia nigra: effects of repeated administration of haloperidol
33. Clozapine increases rat serum prolactin levels
34. Clozapine: neuroendocrine studies of an atypical neuroleptic
35. Coupling of dopamine D-1 recognition sites with adenylate cyclase in nucleus accumbens and caudatus of schizophrenics
36. Efferent connections and nigral afferents of the nucleus accumbens septi in the rat
37. The striatal dopaminergic function is mediated by the inhibition of a nigral, non-dopaminergic system via a striato-nigral GABAergic pathway
38. Superior colliculus lesions selectively attenuate apomorphine-induced oral stereotypy: a possible role for the nigrotectal pathway
39. The effect of 5-hydroxytryptamine synthesis inhibitors on neuroleptic-induced catalepsy in rats
40. Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, loxapine and chlorpromazine
41. Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects
42. GABA: an important moderator and mediator of dopamine-dependent behaviours
43. Antipsychotic drug doses and neuroleptic/dopamine receptors
44. Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists
45. Antischizophrenic drugs and brain cholinergic receptors
46. An anatomy of schizophrenia?
47. GABA blockade, dopamine and schizophrenia: experimental studies in the cat
48. The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (clozapine)
49. D-2 receptor stimulation inhibits cyclic AMP formation brought about by D-1 receptor stimulation in rat neostriatum but not nucleus accumbens
50. The pathophysiologic basis of tardive dyskinesias
51. Effect of different CNS-active drugs on the catalepsy induced by neuroleptics
52. Behavioural correlates of the actions of selective dopamine D-1 receptor antagonists: impact of SCH 23390 and SKF 83566, and functionally interactive D-1:D-2 receptor systems
53. Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat